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http://www.ctajournal.com/content/4/1/22RESEARCH Open AccessAn EAACI “European Survey on Adverse Systemic
Reactions in Allergen Immunotherapy (EASSI)”:
the methodology
Moises A Calderón1*, Pablo Rodríguez del Río2, Carmen Vidal3, Jocelyne Just4, Oliver Pfaar5, Allan Linneberg6,7,8
and Pascal Demoly9Abstract
At present, there is no European report on clinically relevant systemic reactions due to the regular use of allergen
immunotherapy (AIT), administered either subcutaneously or sublingually (SCIT and SLIT, respectively) outside
clinical trials. Using an electronic survey and a “harmonised terminology” according to MedDRA, we aimed to
prospectively collect systemic adverse reactions due to AIT from real life clinical settings.
Under the framework of the EAACI, a team of European specialists in AIT, pharmacovigilance, epidemiology and
drugs regulation set up a web-based prospective pilot survey to be conducted in three European countries (France,
Germany and Spain). A designated “national coordinator” was responsible for following ethics requirements relative
to each country and to select at least 30 doctors per country.
Patients were recruited the same day they received their first dose of either SCIT or SLIT. Patient inclusion criteria
were: adults and children, with IgE mediated pollen, house dust mite, Alternaria, and/or animal dander respiratory
allergies who will initiate AIT.
A list of 31 symptoms terms were extracted from the MedDRA (Medical Dictionary for Regulatory Activities)
dictionary to harmonize the reporting of all adverse systemic reactions in this survey.
The SurveyMonkey® online instrument was used by participant doctors to submit information directly to a blinded
central database.
Three questionnaires were generated: i) the Doctor Questionnaire, ii) the Patient Questionnaire and iii) the Adverse
Reaction Questionnaire. A handbook and a mistake report form were given to each doctor.
In this paper, we describe the methodology followed.
Keywords: Allergen, Adverse systemic reactions, Allergen immunotherapy, Subcutaneous, SublingualIntroduction
Allergen immunotherapy (AIT) is the hallmark of allergic
treatments; its disease course-modifying potential has been
proven for allergic rhinoconjunctivitis and asthma [1-4].
Despite the beneficial effect of AIT on the natural history
of allergic diseases, the potential for systemic adverse reac-
tions may influence its prescription rate.
The reporting of adverse reactions varies according to
the authors and the data collected; therefore, it is very
important to differentiate the parameters used to calculate* Correspondence: m.calderon@imperial.ac.uk
1Section of Allergy and Clinical Immunology, Imperial College London, National
Heart and Lung Institute, Royal Brompton Hospital, London, UK
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reproduction in any medium, provided the or
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unless otherwise stated.the percentage or ratio of adverse reactions after AIT. The
AIT-related systemic reaction rate varies amongst the
published reports. For example, in a retrospective review
of a multicentre AIT database, Roy et al. [5] identified in
258 patients over a period of 2 years, a systemic reaction
(SR) rate of 0.043% of visits and 0.025% of injections.
Furthermore, Greenberg et al. [6] reported a 7% patients’
rate of systemic reactions in a multicenter prospective sur-
vey which included 628 patients (20,588 injections) over a
period of 1 year. More recently, in a surveillance survey
from 2008 to 2011, the American Academy of Allergy,
Asthma & Immunology and the American College of
Allergy, Asthma & Immunology members completed anal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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actions [7]. No fatal reactions were directly or indirectly
reported. The systemic reaction rates were similar for all
3 years (0.1% of injection visits; 83% of practices), as were
severity grades. On average, for all 3 years, there were 7.1
grade 1 (mild reactions, urticaria or upper respiratory tract
symptoms), 2.6 grade 2 (moderate reactions, reduction in
lung function with or without other organs involvement),
and 0.4 grade 3 (severe reactions, life-threatening anaphyl-
axis) SRs per 10,000 injection visits.
Upon reporting adverse systemic reactions, some clin-
ical and methodological factors should be considered;
these are: i) patient characteristics (severity of allergic
disease, co-morbidities, risks factors), ii) type of allergen
extract (native or chemically modified allergen, aqueous,
depot or adjuvanted), iii) the route of administration of
AIT (SCIT or sublingual, SLIT), iv) the dose of antigen
given during the up-dosing and maintenance phases, v)
the schedule used (conventional, cluster or rush) and, vi)
the experience of the treating physician in the early identi-
fication and treatment of the systemic reaction.
In the late 80s, 26 cases of fatal reactions occurred in
the UK due to the administration of SCIT [8]. The main
factors involved in these fatal reactions were the non-
specialised prescription of AIT by general practitioners
and the lack of medical surveillance after the administra-
tion of SCIT. In the US, 74 fatal reactions occurred from
1973 to 2001 [9-12]. In a US survey [11], it was estimated
that fatal reactions occurred once per 2.5 million injections,
with an average of 3.4 deaths per year. In this report there
were 20 cases directly reported and 21 cases indirectly
reported of fatal reactions to AIT by local physicians.
A prospective multicentre Italian real-life survey assessed
the safety of SCIT in 1,738 patients [13]. SRs were graded
according to the EAACI recommendations, and were
classified as immediate or delayed. Vaccines were pre-
scribed according to guidelines; only standardized depot
extracts were used. A total of 60,785 injections were given
over a mean SCIT duration of 3 years. Overall, 95 reac-
tions were observed in 57 patients (3.28%), corresponding
to 4.7% of the courses and 1.56/1000 injections. Twenty-
five patients experienced more than one adverse event.
There were 34 grade 2, 60 grade 3 and one grade 4
reactions and no fatality [13].
For SLIT, 11 case reports of anaphylaxis (all non-fatal)
have been published [14]. These cases were diagnosed
according to the World Allergy Organization criteria [15].
The extremely low incidence of systemic serious adverse
reactions in the European experience supports its indica-
tion for home administration.
At present, data regarding adverse reactions to AIT
is retrieved from different sources: clinical develop-
ment (clinical trials), post marketing surveillance and
pharmacovigilance. There is currently no European reportnetwork on adverse reactions (clinically relevant systemic
reactions) in daily practice.
In recent systematic reviews and meta-analyses [16-21],
different authors have highlighted that there is a wide var-
iety of terms and grading systems that have been used to
report adverse reactions to AIT [15,22-24], and this has a
limiting effect upon the comparability between reports.
Despite recent efforts from international allergy societies
in grading reactions [15,25], there is still no harmonisation
in the terminology used when reporting systemic adverse
reactions due to AIT, either SCIT or SLIT.
Considering all these factors, under the framework of
the European Academy of Allergy and Clinical Immun-
ology (EAACI), an electronic pilot survey is conducted
to prospectively follow a cohort of patients receiving
AIT, either SCIT or SLIT. The aim of the study is to
estimate i) the proportion of patients experiencing at
least one systemic adverse reaction, ii) the incidence rate
of systemic reactions in a real life setting and, iii) the
possible risk factors involved in these reactions. For this
purpose it was proposed the use of a harmonised ter-
minology to properly report adverse reactions by using
well-predefined and clearly stated terms following the
MedDRA (Medical Dictionary for Regulatory Activities)
classification [26].
In this paper, the methodology developed to perform a
European prospective electronic survey on clinically
relevant systemic reactions due to AIT, either SCIT or
SLIT, administrated in a real clinical setting and using
a predefined harmonised terminology based on the
MedDRA is described. This pilot survey will precede
and form the basis for a future large-scale European
survey.
Methodology
The EAACI Immunotherapy Interest Group (ITIG) sought
to perform a prospective longitudinal survey to collect in-
formation on systemic adverse reactions of AIT in a real
life setting. It was decided that a pilot survey was needed
to confirm the usefulness of the questionnaires and the
feasibility of using them in real life for future large-scale
European surveys.
Survey team
The survey team was composed of 21 people including a
responsible person (Chair of the EAACI ITIG), an inter-
national survey coordinator, 3 national coordinators, a
survey manager, a survey secretary, a medical survey team
(7 members) and a survey expert advisers’ team (6
members).
Three working teams were created: i) for the question-
naires and survey development, ii) for the selection of the
harmonized terms from MedDRA to describe adverse re-
actions and, iii) for data analysis and reporting. All teams
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nicians performing AIT, pharmacovigilance, epidemiology,
drugs regulation, and institutional EAACI representatives.
Objectives of the survey
The main objectives of the survey were i) to collect infor-
mation of systemic adverse reactions in AIT in real life
practice and, ii) to evaluate the use of a harmonised
MedDRA-based terminology. Secondary objectives were i)
to establish the web support of the survey, ii) to optimise
the logistics of the future pan-European survey based on
this pilot survey and, iii) to offer an estimation on the
sample size needed for a future pan-European survey.
Design of the survey
The survey is to be carried out in a prospective manner,
all patients are recruited on the same day they receive
their first dose of a new AIT treatment, either SCIT or
SLIT, and are followed up until the last day of the survey
with a maximum follow up of 18 months and a mini-
mum of 3 months. Only systemic reactions due to AIT
are registered. The survey started the 1st of September
of 2012 and was completed in February 2014. To keep a
closer control on every variable, this pilot survey is being
conducted in several centres simultaneously in three separ-
ate European countries (France, Germany and Spain). A
designated “national coordinator” is responsible for follow-
ing specific country ethics requirements and for selecting at
least 30 doctors per country.
Design of questionnaires
The SurveyMonkey® online survey instrument was used
[27], allowing participant doctors to store all data collected
on a centralised database. All data filed was protected by an
enhanced security system (Secure Sockets Layer, SSL, a
protocol for encrypting information over the Internet). The
questionnaires were done in accordance with the “checklist
for reporting results of internet e-surveys, CHERRIES” [28].
The survey used a skip logic pattern, allowing partici-
pating doctors to avoid certain sections according to
their responses in preceding questions. The questions
were presented in a fixed order and most of them were
close-ended; however, an optional free text box was sup-
plied in some of the questions to avoid missing unex-
pected information. Most of the questions were designed
to be answered in a compulsory manner. The survey was
then beta tested by 10 doctors in centres of different
countries. Once the questionnaires and the electronic
survey had satisfactory fulfilled all academic and logistical
issues, they were emailed by the “Survey Coordinator”
to each participant’s survey doctor, named the “Survey
Doctor”. The survey was designed as a “closed survey” with
an individual study doctor’s code and password controlling
access to each questionnaire. Once the questionnaires werecompleted, respondents were allowed to review and change
their answers, but after they were “submitted”, answers
could not be modified anymore.
Blinding
Assuring doctors’ anonymity was crucial for this type of
survey, collecting any kind of mistakes and other sensitive
information. For this purpose, two separate databases
were created. The first database contained names and
contact details of participating study doctors, together
with an individual numerical identification code for the
survey. The second database contained only the survey
information extracted from the 3 questionnaires. The
Survey International Coordinator is the only person
with access to the first database, enabling contact with
any study doctor if any clarification regarding patient
data was needed. Access to the second database was
allowed only to the team responsible for the analysis of
the survey data (Figure 1).
Results
Questionnaires
Three specific electronic questionnaires were designed.
Questions were modified slightly in accordance to ethic
committees’ recommendations or requests in each partici-
pating country, although no changes in the main body of
the survey were required.
The 3 questionnaires generated are: i) Doctor’s Ques-
tionnaire (DQ), ii) Patient’s Questionnaire (PQ) and, iii)
Adverse Reactions Questionnaire (RQ).
i) Doctor’s Questionnaire (DQ) (Additional file 1).
This is the first questionnaire to be completed, and
the survey doctor should fill it in only once. It is
composed of 9 questions; its completion takes 2–3
minutes. The DQ includes information about the
doctor prescribing AIT, such as his/her speciality,
clinical experience (in years), setting of practice
(public or private), percentage of new patients they
prescribed to receive AIT in the previous year and
the percentage of SCIT or SLIT treatments
prescribed in the previous year.
ii) Patient’s Questionnaire (PQ) (Additional file 2). This
questionnaire should be completed once per each
new patient and AIT course included in the survey.
It comprises 25 to 34 questions, depending on the
options chosen; its completion takes 6–8 minutes. The
PQ includes: demographic data of the patient
(age, gender), baseline medical history (cardio-vascular
problems and other clinically relevant chronic
diseases), allergy history (asthma, rhinitis, urticaria,
atopic dermatitis, conjunctivitis and food-, drug- or
hymenoptera-allergy), any current treatment, patient’s
allergic profile (skin prick tests (SPTs), sIgE, clinically
Figure 1 EASSI pilot-survey working flow diagram.
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details of the prescribed AIT that will be followed up,
along with the survey (onset, composition, route,
extract, formulation, schedule, premedication).
iii)Systemic Adverse Reactions Questionnaire (RQ)
(Additional file 3). This questionnaire was designed
to be used only in the event of a systemic adverse
reaction occurring in a patient included in this
survey. It comprises 17 to 21 questions; its
completion takes 4–6 minutes. The data collected
includes: treatment phase when the reaction
occurred (up-dosing or maintenance), elapsed time
from application to onset of systemic adverse
reaction, symptoms, treatment used to control the
reaction, severity, seriousness, causality, co-factors
identified that may have triggered the adverse reaction,
duration, and the final outcome of the reaction. It wasalso asked whether the treatment was discontinued or
not; in case it was not discontinued, information was
also requested about any modification to the AIT
schedule. If a serious adverse event occurs, the survey
doctors were advised to forward the information to
their national authorities and to follow the reporting
procedures established in their countries.
A survey handbook with a brief explanation of every
question as well as some key points of the survey was
prepared by the medical team and distributed to all
participating doctors.
Minimising data-entry mistakes
In the event that participating survey doctors were aware
they had made a mistake entering data, they were advised
to complete a Report of Mistakes Form indicating the type
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national survey coordinator. A record of all mistakes and
changes was kept.
Data quality assessment
The survey international coordinator and the survey
manager carried out a monthly systematic review of the
database, searching for inconsistencies. If duplicated
patients, missing information or any other error was
detected, the survey international coordinator generated
a query and contacted the study doctor responsible of that
questionnaire for clarification. When a mistake was identi-
fied, and after double checking, the mistake was removed
and the correct data was introduced into the database.
Tracked changes of all errors detected were kept at all
times.
Recruitment
Potential participating survey doctors were recruited by
the corresponding national coordinator. Several methods
were used such as direct phone calls, emails, open calls
and seminars in National and Regional meetings and
congresses. Participants were not supported by any fee.
Nevertheless, all participant doctors are acknowledged at
the end of the paper and those from centres contributing
larger numbers of patients are given the option to be
named as authors in the publication.
Once doctors accepted to participate, they contacted
the survey international coordinator who responded with
an introductory email containing a formal invitation, the
survey protocol, the survey handbook, and 3 uniform
resource locators (URLs) to access each questionnaire
(Figure 1).
The survey doctor’s inclusion criteria were: to have
access to the internet, to have knowledge of English (to
understand written English), to administrate AIT (either
SCIT or SLIT) as a part of his/her regular clinical practice
duties, and to commit to personally collect and transfer
the information into the survey database.
Patient’s in/exclusion criteria
The patient inclusion criteria for the survey were: adults
and children, males and females, patients with IgE medi-
ated pollen and/or house dust mite, and/or Alternaria,
and/or animal dander respiratory allergies who would
initiate AIT, either SCIT or SLIT, according to real-life
clinical standards of practice. Patients undergoing pre- or
co-seasonal treatment might only be included if their first
administration of the whole AIT course was during the
survey period. Patients could be included in this survey if
previous AIT courses had been performed and finished
in the past, regardless of the gap between the end of
the previous treatment and the start of the new one.
Patients undergoing more than one AIT could be included,by completing one PQ for each treatment. Exclusion
criteria were: other AIT including venom, moulds
other than Alternaria, and food immunotherapy.
Ethics
European Union and specific country ethics, and regu-
latory requirements, including data protection, were
followed. Each survey’s national coordinator was respon-
sible for addressing the corresponding ethics’ committee.
Harmonised MedDRA terminology
Prior to initiation of the pilot survey, it was decided that
all symptoms described as “systemic adverse reactions”
will be reported using the MedDRA terms [26]. MedDRA
is a clinically validated international medical terminology
used to classify adverse events information associated with
the use of biopharmaceuticals and other medical products,
allowing health authorities and industry to exchange and
analyse data related to the safe use of medical products.
The use of MedDRA terminology is supported by different
international agencies including the European Medicines
Agency (EMA).
Since 2003 it has been mandatory to submit all serious
adverse events electronically using this dictionary. The
MedDRA dictionary is organised by System Organ Class
(SOC), divided into High-Level Group Terms (HLGT),
High-Level Terms (HLT), Preferred Terms (PT) and finally
into Lower-Level Terms (LLT).
After reviewing literature, the medical team selected
31 LLT medical terms from the MedDRA dictionary, to
describe the nature of any adverse event elicited during
an AIT course (Table 1). Besides these 31 terms, a free
text box was provided to gather any unexpected terms
that could have been undervalued by the medical team.
The included terms are: abdominal pain, angioedema,
asthma, blood pressure decrease, bronchospasm, chest
discomfort, chest tightness, conjunctivitis allergic, cough,
diarrhoea, dysphagia, dysphonia, dyspnoea, dizziness, ery-
thema, fatigue, flushing, generalised erythema, headache,
hypotension, laryngeal oedema, loss of consciousness,
nausea, generalized pruritus, allergic rhinitis, sensation of
foreign body, syncope, tachycardia, urticaria, vomiting and
wheezing. Additional descriptions were added to some to
avoid misunderstanding for and from the survey doctors.
There was no attempt to group them into different
severities.
Statistics
The proportion of patients experiencing systemic reac-
tions during the study period among patients included
in the survey will be calculated. 95% confidence intervals
(CI) will be based on the binomial distribution. Inde-
pendent effects of risk factors for systemic effects will
be assessed by logistic regression analyses. The observed
Table 1 Selected medical terms from the MedDRA dictionary used in this survey for recording systemic adverse
reactions
SOC PT LLT
Cardiac disorders Tachycardia Tachycardia
Eye disorders Conjunctivitis allergic Conjunctivitis allergic
Gastrointestinal disorders Abdominal pain Abdominal pain
Diarrhoea Diarrhoea
Dysphagia Dysphagia
Nausea Nausea
Vomiting Vomiting
General disorders and administration site conditions Chest discomfort Chest discomfort
Chest discomfort Chest tightness
Fatigue Fatigue
Sensation of foreign body Sensation of foreign body
Investigations Blood pressure decreased Blood pressure decreased
Nervous system disorders Dizziness Dizziness
Headache Headache
Loss of consciousness Loss of consciousness
Syncope Syncope
Respiratory, thoracic and mediastinal disorders Asthma Asthma
Bronchospasm Bronchospasm
Cough Cough
Dysphonia Dysphonia
Dyspnoea Dyspnoea
Laryngeal oedema Laryngeal oedema
Rhinitis allergic Rhinitis allergic
Wheezing Wheezing
Skin and subcutaneous tissue disorders Angioedema Angioedema
Erythema Erythema
Generalised erythema Generalised erythema
Pruritus generalised Pruritus generalized
Urticaria Urticaria
Vascular disorders Flushing Flushing
Hypotension Hypotension
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the within country/region patient populations in the
future large-scale implementation of the survey.
Data protection
As part of the security measures in the handling and
processing of the survey data, it was established that the
only authorised person to have access to all information
collected by the survey doctors is the survey international
coordinator. This person has access to all codes, electronic
addresses and personal information of all survey doctors.
Regarding patients’ information, there is no chain link to
any patient included in the survey. For each patient, anindividual national code is created. This code will allow
the survey international coordinator to extract any rele-
vant information in case of any systemic adverse reaction.
The SurveyMonkey® facility utilises some of the most
advanced technology for Internet security commercially
available today. To use this tool, as administrator, a unique
user name and password must be entered. SurveyMonkey®
issues a session “cookie” only to record encrypted au-
thentication information for the duration of a specific
session. Once the user accesses secured areas, the
Secure Sockets Layer (SSL) technology protects user
information using both server authentication and data
encryption, ensuring that user data is safe, secure, and
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PCI-DSS compliant.
Discussion
Based on the academic platform provided by the EAACI,
and considering the current lack of information regard-
ing a registry of systemic adverse reactions due to AIT
in clinical practice settings across Europe, this electronic
survey represents a much-needed and useful tool. The
questions included in the three survey questionnaires
allow collecting relevant information in a simple, practical,
non-commercial and friendly manner.
The general information regarding the survey doctor’s
profile requested in the first questionnaire will allow to
recognize which factors associated with the AIT pre-
scription are related to doctors themselves. It will be
evaluated if specialty (allergy vs non-allergy training)
and the years of clinical practice may play a role in the
selection of patients for AIT and in the early recognition
of systemic adverse reactions after AIT and their prompt
treatment.
Regarding the patient’s questionnaire, our survey will
allow recognition of the factors most commonly linked
to systemic adverse reactions. This will be an indirect
way of determining risk factors. Attention has been
placed upon patients’ medical and allergic history, status
of their allergic profile (including other co-allergies),
previous successful and non-successful AIT, and previ-
ous reactions to AIT. Data on the route of AIT adminis-
tration, the type of allergens used (native vs allergoid
allergens) and the time when reactions occur (build-up
vs maintenance phase) will be collected. This survey was
designed to collect all possible systemic reactions occur-
ring at AIT clinical practices in real life settings, not as
part of clinical trials.
We are aware that total number of doses administered
will only give an estimate, and not a specific number
since some of the SCIT doses can be administered else-
where from the doctor’s AIT unit. Patients receiving
SLIT were instructed to report any reaction related to
treatment which may occur at any time during the study.
SLIT doses calculation will be based upon reporting by
patients, and not on the count of empty blisters/vials. As
mentioned, the incidence rate (number of reactions per
patient per month/year of treatment or even better per
injection/dose) would probably be more appropriate.
Hopefully this may also be calculated, at least as some
indirect measure.
It can be argued that adverse events are linked to
higher doses of major allergen and thus, some data of
efficacy should be provided as a direct sign of good dos-
age. Again, this survey tries to mirror daily practice and
is also aimed to keep it simple, which is why no efficacy
parameters are measured.Only adverse reactions due to AIT for aero-allergens
will be recorded, this will provide a more homogeneous
treatment modality to be evaluated. For this reason,
venom immunotherapy was excluded in this survey. All
moulds except for Alternaria were also excluded because
of the weaker clinical evidence supporting their use in
AIT.
Different classifications have been used to record and
score adverse reactions due to AIT [15,22-24]. For this
survey it was decided to take a different approach;
instead of collecting the reactions according to the grade
provided by each doctor (which varies considerably),
each reaction is described by their single symptoms
using the MedDRA classification. This will provide a
more detailed description of each reaction, and could
also be used to help the future creation of real-life classi-
fications or even allow further collaborations with EMA
in the process of registration of any AIT product. The
reactions questionnaire was designed to be in accordance
with EMA recommendations with respect to the commu-
nication of adverse drug reactions
The human team is the key factor in the success of
this survey due to their generous collaboration. Despite
its reduced budget, this survey has become a reality that
will deliver outstanding data concerning one of the most
sensitive factors of clinical allergy: systemic adverse reac-
tions resulting from AIT.
Additional files
Additional file 1: Doctor’s Questionnaire.
Additional file 2: Patient’s Questionnaire.
Additional file 3: Systemic Adverse Reactions’ Questionnaire.
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